002932 明德生物
已收盘 04-03 15:00:00
资讯
新帖
简况
明德生物（002932）披露首次回购公司股份暨回购进展公告，4月3日股价下跌1.66%
证券之星 · 04-03 18:53
明德生物（002932）披露首次回购公司股份暨回购进展公告，4月3日股价下跌1.66%
4月1日明德生物涨7.73%，鑫元专精特新混合A基金重仓该股
证券之星 · 04-01 16:16
4月1日明德生物涨7.73%，鑫元专精特新混合A基金重仓该股
明德生物披露收购蓝帆医疗全资子公司股权交易进展
中金财经 · 03-31
明德生物披露收购蓝帆医疗全资子公司股权交易进展
明德生物（002932）披露回购股份事项前十名股东持股情况，3月25日股价下跌5.39%
证券之星 · 03-25
明德生物（002932）披露回购股份事项前十名股东持股情况，3月25日股价下跌5.39%
3月25日明德生物跌5.39%，鑫元专精特新混合A基金重仓该股
证券之星 · 03-25
3月25日明德生物跌5.39%，鑫元专精特新混合A基金重仓该股
明德生物（002932）披露关于公司股票交易可能被实施退市风险警示的提示性公告，3月23日股价下跌10.02%
证券之星 · 03-23
明德生物（002932）披露关于公司股票交易可能被实施退市风险警示的提示性公告，3月23日股价下跌10.02%
明德生物业绩预告修正后“变脸”；三叶草生物与全球疫苗免疫联盟和解 | 医药早参
每日经济新闻 · 03-23
明德生物业绩预告修正后“变脸”；三叶草生物与全球疫苗免疫联盟和解 | 医药早参
披星戴帽预警！明德生物业绩预告“变脸”
市场资讯 · 03-22
披星戴帽预警！明德生物业绩预告“变脸”
002932，可能被实施退市风险警示！公司：目前生产经营正常！
e公司 · 03-22
002932，可能被实施退市风险警示！公司：目前生产经营正常！
明德生物最新公告：股票可能被实施退市风险警示
证券之星 · 03-22
明德生物最新公告：股票可能被实施退市风险警示
明德生物（002932）披露重大资产重组进展公告，2月27日股价上涨0.37%
证券之星 · 02-27
明德生物（002932）披露重大资产重组进展公告，2月27日股价上涨0.37%
股市必读：明德生物(002932)股东户数2.4万户，较上期减少3.06%
证券之星 · 02-25
股市必读：明德生物(002932)股东户数2.4万户，较上期减少3.06%
明德生物新注册《EasyPoint POCT智慧管理系统V1.0.0》项目的软件著作权
证券之星 · 02-12
明德生物新注册《EasyPoint POCT智慧管理系统V1.0.0》项目的软件著作权
明德生物两笔收购背后的隐忧：主业承压下的扩张赌局？
新浪证券 · 02-06
明德生物两笔收购背后的隐忧：主业承压下的扩张赌局？
明德生物（002932）披露增资并收购蓝怡（湖南）医疗器械有限公司股权进展公告，2月5日股价上涨0.21%
证券之星 · 02-05
明德生物（002932）披露增资并收购蓝怡（湖南）医疗器械有限公司股权进展公告，2月5日股价上涨0.21%
股市必读：明德生物（002932）预计2025年全年扣非后净利润亏损7800万元至9800万元
证券之星 · 02-02
股市必读：明德生物（002932）预计2025年全年扣非后净利润亏损7800万元至9800万元
双线并购补短板，明德生物密集推进股权收购计划
新京报 · 01-30
双线并购补短板，明德生物密集推进股权收购计划
明德生物（002932）披露重大资产重组进展公告，1月29日股价下跌0.77%
证券之星 · 01-29
明德生物（002932）披露重大资产重组进展公告，1月29日股价下跌0.77%
明德生物(002932)1月20日股东户数2.48万户，较上期减少15.73%
证券之星 · 01-28
明德生物(002932)1月20日股东户数2.48万户，较上期减少15.73%
明德生物：公司收购围绕主业协同与核心竞争力提升展开
证券之星 · 01-28
明德生物：公司收购围绕主业协同与核心竞争力提升展开
加载更多
公司概况
公司名称：
武汉明德生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2018-07-10
主营业务：
武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公司的主要产品是体外诊断试剂和仪器、急危重症信息化解决方案、第三方医学检验服务。2023年2月，公司被授予2022年度“光谷质量奖·卓越奖”，此次荣获“光谷质量奖·卓越奖”是东湖高新区对公司高质量发展的充分认可及鼓励。2024年2月，公司被武汉市人民政府授予“第八届武汉市市长质量奖”。
发行价格：
20.45
{"stockData":{"symbol":"002932","market":"SZ","secType":"STK","nameCN":"明德生物","latestPrice":16.6,"timestamp":1775199825000,"preClose":16.88,"halted":0,"volume":6611814,"delay":0,"changeRate":-0.0166,"floatShares":156000000,"shares":233000000,"eps":0.0306,"marketStatus":"已收盘","change":-0.28,"latestTime":"04-03 15:00:00","open":16.8,"high":16.85,"low":16.38,"amount":109000000,"amplitude":0.0278,"askPrice":16.6,"askSize":19,"bidPrice":16.59,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.0306,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.88,"symbolType":"stock","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":18.57,"lowLimit":15.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":232520957,"isCdr":false,"pbRate":0.71,"roa":"--","peRate":542.48366,"roe":"0.24%","epsLYR":0.33,"committee":-0.104693,"marketValue":3860000000,"turnoverRate":0.0424,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-08。","floatMarketCap":2591000000},"requestUrl":"/m/hq/s/002932","defaultTab":"news","newsList":[{"id":"2624654439","title":"明德生物（002932）披露首次回购公司股份暨回购进展公告，4月3日股价下跌1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654439","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654439?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:53","pubTimestamp":1775213591,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，明德生物报收于16.6元，较前一交易日下跌1.66%，最新总市值为38.6亿元。该股当日开盘16.8元，最高16.85元，最低16.38元，成交额达1.09亿元，换手率为4.24%。公司于近日披露《关于首次回购公司股份暨回购进展的公告》。本次回购符合相关法律法规及公司已披露的回购方案。公司后续将在回购期限内继续实施回购，并按规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300036089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595335","title":"4月1日明德生物涨7.73%，鑫元专精特新混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624595335?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:16","pubTimestamp":1775031366,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日明德生物涨7.73%，收盘报17.29元，换手率9.06%，成交量14.15万手，成交额2.37亿元。重仓明德生物的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为鑫元基金的鑫元专精特新混合A。鑫元专精特新混合A目前规模为0.94亿元，最新净值0.6746，较上一交易日下跌0.52%，近一年上涨22.65%。该公募基金现任基金经理为陆杨。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399267","002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623376073","title":"明德生物披露收购蓝帆医疗全资子公司股权交易进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2623376073","media":"中金财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623376073?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:57","pubTimestamp":1774922221,"startTime":"0","endTime":"0","summary":"中国经济网3月31日讯 武汉明德生物科技股份有限公司3月30日《关于重大资产重组进展的公告》披露其拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品有限公司100%股权的最新进展。此次交易若完成，武汉必凯尔将成为明德生物的全资子公司，进一步拓展其在应急救护领域的布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260331/32114942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002382","BK0251","BK0239","BK0077","BK0114","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622740250","title":"明德生物（002932）披露回购股份事项前十名股东持股情况，3月25日股价下跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622740250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622740250?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:15","pubTimestamp":1774448124,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，明德生物报收于16.34元，较前一交易日下跌5.39%，最新总市值为37.99亿元。近日，武汉明德生物科技股份有限公司披露《关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告》。前十名股东中，陈莉莉持股62,918,895股，占比27.06%，位列第一；王颖持股35,916,906股，占比15.45%，位列第二。前十名无限售条件股东中，陈莉莉持有无限售流通股15,729,724股，占比10.08%，位列第一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500043859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622694025","title":"3月25日明德生物跌5.39%，鑫元专精特新混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622694025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622694025?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:26","pubTimestamp":1774427163,"startTime":"0","endTime":"0","summary":"证券之星消息，3月25日明德生物跌5.39%创60日新低，收盘报16.34元，换手率8.04%，成交量12.55万手，成交额2.08亿元。3月25日的资金流向数据方面，主力资金净流出1221.66万元，占总成交额5.87%，游资资金净流入3040.02万元，占总成交额14.62%，散户资金净流出1818.35万元，占总成交额8.74%。重仓明德生物的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为鑫元基金的鑫元专精特新混合A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500030663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","399267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621774183","title":"明德生物（002932）披露关于公司股票交易可能被实施退市风险警示的提示性公告，3月23日股价下跌10.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621774183?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:56","pubTimestamp":1774259803,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，明德生物报收于16.61元，较前一交易日下跌10.02%，最新总市值为38.62亿元。该股当日开盘16.61元，最高16.61元，最低16.61元，成交额达4646.32万元，换手率为1.79%。明德生物于近日披露《关于公司股票交易可能被实施退市风险警示的提示性公告》。根据《深圳证券交易所股票上市规则》相关规定，公司股票交易可能在2025年年度报告披露后被实施退市风险警示。最终财务数据以经审计的2025年年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621742895","title":"明德生物业绩预告修正后“变脸”；三叶草生物与全球疫苗免疫联盟和解 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742895","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621742895?lang=zh_cn&edition=full","pubTime":"2026-03-23 07:00","pubTimestamp":1774220407,"startTime":"0","endTime":"0","summary":"丨2026年3月23日星期一丨NO.1三叶草生物与全球疫苗免疫联盟就仲裁事项达成和解3月22日，三叶草生物发布公告，称三叶草香港与全球疫苗免疫联盟已订立和解协议，据此，此前仲裁将获得全面及最终解决，而全球疫苗免疫联盟就该仲裁向三叶草香港提出的所有申索，将于支付有关款项后获撤回及解除。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233679868895.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679868895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","159646","BK0239","BK1574","002932","BK1161","159938","09939","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621712824","title":"披星戴帽预警！明德生物业绩预告“变脸”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621712824","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621712824?lang=zh_cn&edition=full","pubTime":"2026-03-22 19:03","pubTimestamp":1774177380,"startTime":"0","endTime":"0","summary":" 原本预计2025年归属净利润盈利的明德生物，于3月22日晚间突然发布业绩预告修正公告称，公司归属净利润将出现亏损。 针对下修业绩预告的原因，明德生物表示，公司在披露2025年度业绩预告时，年度审计工作尚未全面开展，相关财务数据及信息尚处于初步整理阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-22/doc-inhrwism6046022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719708","title":"002932，可能被实施退市风险警示！公司：目前生产经营正常！","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719708","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719708?lang=zh_cn&edition=full","pubTime":"2026-03-22 16:31","pubTimestamp":1774168260,"startTime":"0","endTime":"0","summary":"3月22日，明德生物发布修正业绩预告，由于其预计2025年度经审计后的利润总额、净利润、扣除非经常性损益后的净利润为负值，且扣除后的营业收入低于3亿元，公司股票交易可能在2025年年报披露后被深交所实施退市风险警示。 不过，公司在公告中表示，目前生产经营一切正常。 今年1月19日，明德生物公告称，拟以3570.10万元通过增资及股权收购方式取得湖南蓝怡51%股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-22/doc-inhrwcks2004739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719368","title":"明德生物最新公告：股票可能被实施退市风险警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719368?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:40","pubTimestamp":1774165252,"startTime":"0","endTime":"0","summary":"明德生物(002932.SZ)公告称，公司预计2025年度利润总额亏损0.5亿元至0.75亿元，净利润亏损0.15亿元至0.25亿元，扣非净利润亏损1亿元至1.4亿元，扣除后的营业收入为2.37亿元至2.97亿元。因净利润为负且扣除后营收低于3亿元，公司股票可能在2025年年报披露后被实施退市风险警示(*ST)。目前年报审计工作仍在进行，最终数据以经审计的年报为准。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200002994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614850063","title":"明德生物（002932）披露重大资产重组进展公告，2月27日股价上涨0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614850063","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614850063?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:33","pubTimestamp":1772206391,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，明德生物报收于18.75元，较前一交易日上涨0.37%，最新总市值为43.6亿元。该股当日开盘18.75元，最高18.79元，最低18.62元，成交额达2101.08万元，换手率为0.72%。近日，明德生物披露《关于重大资产重组进展的公告》。公告显示，公司拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品有限公司100%股权，本次交易预计构成重大资产重组，不构成重组上市，不涉及发行股份，也不构成关联交易。本次交易存在较大不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614749017","title":"股市必读：明德生物(002932)股东户数2.4万户，较上期减少3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614749017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614749017?lang=zh_cn&edition=full","pubTime":"2026-02-25 01:31","pubTimestamp":1771954269,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，明德生物报收于18.85元，上涨0.8%，换手率0.77%，成交量1.21万手，成交额2271.85万元。当日关注点来自交易信息汇总：2月24日主力资金净流出248.51万元，散户资金净流入469.29万元。股本股东变化股东户数变动近日明德生物披露，截至2026年1月31日公司股东户数为2.4万户，较1月20日减少758.0户，减幅为3.06%。户均持股数量由上期的9389.0股增加至9686.0股，户均持股市值为18.65万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500000856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610509039","title":"明德生物新注册《EasyPoint POCT智慧管理系统V1.0.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610509039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610509039?lang=zh_cn&edition=full","pubTime":"2026-02-12 02:01","pubTimestamp":1770832876,"startTime":"0","endTime":"0","summary":"证券之星消息，近日明德生物新注册了《EasyPoint POCT智慧管理系统V1.0.0》项目的软件著作权。今年以来明德生物新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了4681.89万元，同比减15.22%。通过天眼查大数据分析，武汉明德生物科技股份有限公司共对外投资了24家企业，参与招投标项目706次；财产线索方面有商标信息183条，专利信息218条，著作权信息101条；此外企业还拥有行政许可699个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200001298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609568121","title":"明德生物两笔收购背后的隐忧：主业承压下的扩张赌局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2609568121","media":"新浪证券","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609568121?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:11","pubTimestamp":1770365460,"startTime":"0","endTime":"0","summary":"一个月内，体外诊断上市公司明德生物接连宣布两笔股权收购，引发市场关注与争议。在自身业绩连续下滑、市值“破净”的背景下，公司仍选择收购一家净资产为负、连续亏损的企业，这究竟是战略布局，还是一场危险的资本赌局？ 明德生物近年业绩并不乐观。然而，当收购方自身业绩疲软、标的公司财务状况堪忧时，此类扩张更应慎之又慎。明德生物的两笔收购能否真正提升核心竞争力、带来可持续盈利，仍需时间检验。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-06/doc-inhkwnki2085513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609309787","title":"明德生物（002932）披露增资并收购蓝怡（湖南）医疗器械有限公司股权进展公告，2月5日股价上涨0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309787","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309787?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:33","pubTimestamp":1770301993,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，明德生物报收于19.26元，较前一交易日上涨0.21%，最新总市值为44.78亿元。公告显示，公司于2026年1月19日召开第五届董事会第三次会议，审议通过增资并收购蓝怡（湖南）医疗器械有限公司股权的议案。截至本公告日，湖南蓝怡已完成工商变更登记，公司持有其51%股权，湖南蓝怡成为公司控股子公司，纳入合并报表范围。嘉善禾欣咨询管理合伙企业受让蓝怡集团持有的湖南蓝怡20%股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","09996","BK1100","BK1222","09997","BK0239","159883","002932","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608095889","title":"股市必读：明德生物（002932）预计2025年全年扣非后净利润亏损7800万元至9800万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608095889","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608095889?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:06","pubTimestamp":1769976376,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，明德生物报收于19.26元，下跌0.47%，换手率2.11%，成交量3.3万手，成交额6358.36万元。明德生物发布业绩预告，预计2025年全年归属净利润盈利1200万元至1800万元。2025年度业绩预告武汉明德生物科技股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为1,200万元至1,800万元，比上年同期下降75.85%至83.90%；扣除非经常性损益后的净利润为-9,800万元至-7,800万元，较上年同期亏损收窄，同比增长30.17%至44.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607412011","title":"双线并购补短板，明德生物密集推进股权收购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2607412011","media":"新京报","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607412011?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:53","pubTimestamp":1769770380,"startTime":"0","endTime":"0","summary":"武汉明德生物科技股份有限公司近期瞄准应急救护与体外诊断仪器赛道，接连发起股权收购。明德生物此次收购意在聚焦急危重症业务板块发展。1月29日晚，明德生物再发重大资产重组进展公告，本次交易拟采用现金方式，具体交易方案仍在商讨论证中，交易各方尚未签署正式协议，本次交易尚存在较大不确定性。在披露上述资产收购意向后不久，明德生物又披露了另一则股权收购计划。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261301849492889761.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261301849492889761.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769770404168200.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769770404168200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","002932"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607394190","title":"明德生物（002932）披露重大资产重组进展公告，1月29日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607394190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607394190?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:18","pubTimestamp":1769699893,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，明德生物报收于19.35元，较前一交易日下跌0.77%，最新总市值为44.99亿元。该股当日开盘19.51元，最高19.61元，最低19.21元，成交额达7365.34万元，换手率为2.43%。近日，明德生物发布《关于重大资产重组进展的公告》。本次交易尚存在较大不确定性，公司将根据进展履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606579143","title":"明德生物(002932)1月20日股东户数2.48万户，较上期减少15.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606579143","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606579143?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:32","pubTimestamp":1769592759,"startTime":"0","endTime":"0","summary":"证券之星消息，近日明德生物披露，截至2026年1月20日公司股东户数为2.48万户，较12月31日减少4622.0户，减幅为15.73%。在医疗器械行业个股中，明德生物股东户数高于行业平均水平，截至1月20日，医疗器械行业平均股东户数为2.19万户。从股价来看，2025年12月31日至2026年1月20日，明德生物区间跌幅为1.72%，在此期间股东户数减少4622.0户，减幅为15.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800030101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606752791","title":"明德生物：公司收购围绕主业协同与核心竞争力提升展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2606752791","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606752791?lang=zh_cn&edition=full","pubTime":"2026-01-28 09:06","pubTimestamp":1769562378,"startTime":"0","endTime":"0","summary":"证券之星消息，明德生物01月27日在投资者关系平台上答复投资者关心的问题。公司收购围绕主业协同与核心竞争力提升展开，通过夯实主业提升内在价值。标的选择聚焦产业链互补，旨在进一步提升公司综合服务能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800008276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002932","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775243777648,"stockEarnings":[{"period":"1week","weight":0.0197},{"period":"1month","weight":-0.07},{"period":"3month","weight":-0.1345},{"period":"6month","weight":-0.1277},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.1345}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉明德生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24007人(较上一季度减少3.06%)","perCapita":"6502股","listingDate":"2018-07-10","address":"湖北省武汉市江夏区东湖新技术开发区九龙中路77号武汉明德生物科技产业园(一期)(全部自用)1栋1单元1层1号C区","registeredCapital":"23252万元","survey":" 武汉明德生物科技股份有限公司的主营业务是体外诊断试剂和诊断仪器的研发、生产、销售和服务。公司的主要产品是体外诊断试剂和仪器、急危重症信息化解决方案、第三方医学检验服务。2023年2月，公司被授予2022年度“光谷质量奖·卓越奖”，此次荣获“光谷质量奖·卓越奖”是东湖高新区对公司高质量发展的充分认可及鼓励。2024年2月，公司被武汉市人民政府授予“第八届武汉市市长质量奖”。","listedPrice":20.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"明德生物(002932)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供明德生物(002932)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"明德生物,002932,明德生物股票,明德生物股票老虎,明德生物股票老虎国际,明德生物行情,明德生物股票行情,明德生物股价,明德生物股市,明德生物股票价格,明德生物股票交易,明德生物股票购买,明德生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"明德生物(002932)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供明德生物(002932)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}